Clinical Trials
The Department of Neurology is actively involved in clinical trials to determine the effectiveness of new medications to treat neuromuscular
diseases and disorders. If you are interested in receiving additional information or participating in a trial, please e-mail or call the
persons listed below. Please note that enrollment is currently closed for some of the trials.
Multiple Sclerosis (MS) - Completed Trials; data being analyzed
| BEYOND Study for Relapsing/Remitting MS |
|
| Enrollment is CLOSED; data is being analyzed |
|
The purpose of this two year study is to determine:
- If an experimental dose of a currently approved drug is safe, tolerable, and more effective than the currently approved dose.
- Which of two commonly used drugs is safer, more tolerable, and more effective in treating this disease.
|
| Principle Investigator:
| Barry Arnason MD |
| Sub-Investigator(s):
| Roumen Balabanov MD, Adil Javed MD, Agnes Kim MD, Avertano Noronha MD, Anthony Reder MD, Darshan Shah MD |
| Study Coordinator:
| Mildred Valentine |
| Novantrone in MS |
|
| Enrollment is CLOSED; data is being analyzed |
|
This is a phase IV monitoring study of the effects of Mitoxantrone/Novantrone in active MS. This drug was recently approved by the FDA, and is a form of chemotherapy that reduces the white blood cells that attack the brain. WBC, liver function, and cardiac function will be monitored.
|
| Principle Investigator:
| Anthony Reder MD |
| Study Coordinator:
| Mildred Valentine |
| Rebif vs. Copaxone in Relapsing/Remitting MS |
|
| Enrollment is CLOSED; data are being analyzed |
|
The purpose of this study is to compare the safety and effectiveness of two FDA approved drugs for the treatment of relapsing/remitting MS.
|
| Principle Investigator:
| Anthony Reder MD |
| Sub-Investigator(s):
| Barry Arnason MD, Avertano Noronha MD |
| Study Coordinator:
| Mildred Valentine |
|